Unknown

Dataset Information

0

Next generation of immune checkpoint therapy in cancer: new developments and challenges.


ABSTRACT: Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance and assist with immune response. In cancer, immune checkpoint pathways are often activated to inhibit the nascent anti-tumor immune response. Immune checkpoint therapies act by blocking or stimulating these pathways and enhance the body's immunological activity against tumors. Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death ligand-1(PD-L1) are the most widely studied and recognized inhibitory checkpoint pathways. Drugs blocking these pathways are currently utilized for a wide variety of malignancies and have demonstrated durable clinical activities in a subset of cancer patients. This approach is rapidly extending beyond CTLA-4 and PD-1/PD-L1. New inhibitory pathways are under investigation, and drugs blocking LAG-3, TIM-3, TIGIT, VISTA, or B7/H3 are being investigated. Furthermore, agonists of stimulatory checkpoint pathways such as OX40, ICOS, GITR, 4-1BB, CD40, or molecules targeting tumor microenvironment components like IDO or TLR are under investigation. In this article, we have provided a comprehensive review of immune checkpoint pathways involved in cancer immunotherapy, and discuss their mechanisms and the therapeutic interventions currently under investigation in phase I/II clinical trials. We also reviewed the limitations, toxicities, and challenges and outline the possible future research directions.

SUBMITTER: Marin-Acevedo JA 

PROVIDER: S-EPMC5856308 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Next generation of immune checkpoint therapy in cancer: new developments and challenges.

Marin-Acevedo Julian A JA   Dholaria Bhagirathbhai B   Soyano Aixa E AE   Knutson Keith L KL   Chumsri Saranya S   Lou Yanyan Y  

Journal of hematology & oncology 20180315 1


Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance and assist with immune response. In cancer, immune checkpoint pathways are often activated to inhibit the nascent anti-tumor immune response. Immune checkpoint therapies act by blocking or stimulating these pathways and enhance the body's immunological activity against tumors. Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death ligan  ...[more]

Similar Datasets

| S-EPMC5385298 | biostudies-other
| S-EPMC10308343 | biostudies-literature
| S-EPMC5994499 | biostudies-literature
| S-EPMC7977302 | biostudies-literature
| S-EPMC8693432 | biostudies-literature
| S-EPMC8339559 | biostudies-literature
| S-EPMC4017329 | biostudies-literature
| S-EPMC10514760 | biostudies-literature
| S-EPMC8484171 | biostudies-literature
| S-EPMC5457688 | biostudies-literature